# V1 Empirics Check — openai/gpt-5.1-codex-mini (Variant A)

**Model:** openai/gpt-5.1-codex-mini
**Variant:** A
**Date:** 2026-03-25T13:02:24.603214

---

**Idea Fidelity**

The paper closely follows the manifest. It exploits the 2016–2021 wave of MAID legalization using the CMS Geographic Variation PUF, targets hospice/inpatient/total/ER spending per capita, and centers on a staggered DiD identification with never-treated controls. The promised focus on Callaway–Sant’Anna estimation is delivered, as is the discussion of “exit option” mechanisms and the attempt to speak to welfare implications. One minor departure: the manifest suggested decomposing spending explicitly into hospice vs. acute components (plus SNF/home health), whereas the paper’s main text reports only a handful of these categories and relegates placebos to robustness. But overall the manuscript faithfully pursues the stated idea.

**Summary**

This short paper estimates the causal effect of the 2016–2021 state-level legalization of Medical Aid in Dying on end-of-life Medicare spending composition using county-year data from the CMS Geographic Variation Public Use File. Employing modern staggered DiD (Callaway–Sant’Anna) with wild-cluster bootstrap inference, the author finds precisely estimated null effects for hospice, inpatient, total spending, and no stable effect on ER visits, casting doubt on the “exit option” hypothesis that MAID availability would shift spending toward hospice. The paper also highlights the dangers of relying on TWFE in staggered settings by showing the sign flip in ER visits once heterogeneity-robust estimators are used.

**Essential Points**

1. **Parallel Trends and Pre-Trends Evidence.** The credibility of the identification hinges on the parallel trends assumption, especially given the small number of treatment cohorts. The paper states that it relies on event studies but does not show the event-study figures/tables in the main text, nor report pre-treatment coefficients or provide placebo leads for all outcomes. Presenting these explicitly (even in an appendix) is essential to reassure readers that pre-treatment trajectories are comparable, particularly since treated states differ systematically on observable spending levels (see Table 1).

2. **Power and Sensitivity to Cohort Heterogeneity.** The null results are interpreted as economically meaningful, but cohort-level power varies widely (e.g., New Mexico alone in 2021). The paper mentions cohort estimates in the appendix but does not present confidence intervals or the implied minimal detectable effects. Without showing how precision evolves with cohort size or ruling out large effects in the earliest cohorts, it is premature to conclude that the exit option has no aggregate impact. A formal power analysis or display of confidence intervals for cohort-specific ATTs is needed to buttress statements about economic significance.

3. **Outcome Measurement and Mechanism.** The main theoretical pathway is that MAID normalizes palliative conversations, yet the outcomes used are per capita standardized spending across all beneficiaries (not just decedents or hospice-eligible patients). It is unclear whether these spending measures closely track the behavior of terminal patients or are overly noisy due to compositional shifts in the general Medicare population. The paper should justify this choice more directly, perhaps by showing that the spending metrics are strongly correlated with terminal-care intensity (or by replicating key results using decedent-only spending, if available) to ensure the empirical strategy aligns tightly with the research question.

**Suggestions**

- **Display Event Study Evidence.** Incorporate the Sun–Abraham event-study graphs/tables for the primary outcomes into the main text or appendix, including point estimates and confidence intervals for the pre-treatment leads. If the figures already exist, refer to them explicitly and summarize their key features (no upward drift, etc.). Without seeing these, readers cannot assess whether the parallel-trends assumption holds, which is central to the DiD credibility.

- **Expand on the Cohort Estimates and Power.** Provide a table with cohort-specific ATTs (e.g., 2016, 2019, 2021) along with their standard errors and sample sizes, ideally in the main results or an appendix table. This will clarify whether the null is driven by low precision in smaller cohorts like New Mexico or by consistently small estimates across all cohorts. Additionally, reporting the minimal detectable effect size (MDE) for the pooled sample and for the most informative cohort would strengthen the economic interpretation. Even a short note on how the confidence intervals translate into possible per-beneficiary cost-shift limits would be useful.

- **Clarify the Unit of Analysis vis-à-vis Terminal Patients.** The manifestation of the “exit option” is primarily among terminal patients, but the outcomes are county-level per capita spending. The author could strengthen the mechanistic link by showing that the outcomes are also meaningful when restricted to decedent populations (if the GV PUF allows that) or by demonstrating that the county-level measures capture end-of-life care proportions (e.g., correlate hospice spending per capita with hospice utilization rates or decedent hospice share). If such breakdowns are unavailable, an explicit discussion of how the chosen outcomes proxy for the intended margin would help.

- **Discuss Alternative Mechanisms for the Null.** The paper briefly speculates about why no effect appears (e.g., secular hospice trends). Expanding this discussion to include the possibility of offsetting forces—such as increased hospice spending for non-terminal reasons, supply constraints, or substitution within hospice intensity—would provide a more nuanced interpretation. Linking this to existing literature on hospice growth ceilings or supply-side frictions could make the contribution more informative.

- **Provide More Details on Placebo Tests and Specifications.** The placebo analyses (SNF, home health) are helpful, but they are limited to TWFE. Consider rerunning these placebos with the Callaway–Sant’Anna estimator to ensure that the null extends to heterogeneity-robust specifications. Similarly, the triple-difference exercise is mentioned briefly; adding a short table (even if relegated to an appendix) detailing this specification would help readers evaluate its contribution to robustness.

- **Be Precise About TWFE Inference.** The wild cluster bootstrap $p$-values are reported for Panel A, but it is unclear whether they adjust for the small number of treated clusters or for the fact that some outcomes have varying sample sizes. It would be useful to explain whether the bootstrap resamples states or state-year residuals, and whether the reported $p$-values correspond to two-sided tests (given the methodological lesson). If cluster-robust SEs differ materially from analytic ones, noting that would improve transparency.

- **Highlight the Policy Interpretation with Quantitative Bounds.** The conclusion that MAID should be evaluated on autonomy grounds hinges on the absence of detectable fiscal impacts. Strengthen this by translating the null into a concrete dollar bound per Medicare beneficiary or total program savings foregone. For instance, if hospice spending increased by at most \$40 per capita, what does that imply for aggregate Medicare spending in the treated states? Providing such a bound makes the policy takeaway sharper for practitioners.

- **Clarify the Role of Always-Treated States.** The main analysis excludes Oregon/Washington/Montana/Vermont, yet Panel B includes them for a robustness check without showing how this affects the Callaway–Sant'Anna estimates. If possible, present the heterogeneous treatment estimates both with and without the early adopters in the same framework to reassure readers that the base results do not hinge on their exclusion.

- **Ensure All Tables/Figures are Fully Explained.** Table 3 (Standardized Effect Sizes) contains many “NA” entries and classifications that are difficult to interpret. Either populate the table with actual estimates or remove it. If the intention is to report effect-size magnitudes, provide the necessary calculations (point estimates, standard deviations) so the classification (e.g., “Moderate negative”) is meaningful. At present, the table raises questions more than it answers.

Overall, the paper makes a useful empirical contribution. Addressing the above points—particularly the identification diagnostics, cohort heterogeneity/power discussion, and tighter linkage between outcomes and mechanism—will strengthen its credibility and policy relevance.
